A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
medinfo@incyte.com1.855.463.3463
eumedinfo@incyte.com+800 00027423
Irvine, California 92618, United States
Los Angeles, California 90033, United States
Chapel Hill, North Carolina 27514, United States
Durham, North Carolina 27705, United States
Houston, Texas 77030, United States
Mainz, 55131, Germany
Roma, 00168, Italy
Kashiwa Chiba, 277-0882, Japan
Seocho-gu, Seoul, 06591, South Korea
Las Palmas de Gran Canaria, 35010, Spain
London, SE1 9RT, United Kingdom